Syndax Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Syndax Pharmaceuticals (SNDX).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

12Buy

1Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$38Upside to Avg. PT+167.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$38
Aug 21, 2026	UBS	David Dai	PT Cut	Buy	$37→$33
Aug 11, 2026	JP Morgan	Anupam Rama	PT Cut	Overweight	$44→$40
Aug 5, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Cut	Buy	$40→$38
Jul 15, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
Jun 12, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
May 22, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
May 13, 2026	UBS	David Dai	PT Cut	Buy	$38→$37
May 1, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$35→$37
Apr 1, 2026	Goldman Sachs	Corinne Johnson	PT Raise	Buy	$28→$34
Mar 31, 2026	Mizuho	Salim Syed	PT Cut	Outperform	$45→$43
Mar 30, 2026	Jefferies	Faisal Khurshid	Assumes	Buy	$48→$40
Mar 9, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$33→$45
Mar 2, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$51→$57
Dec 9, 2025	BTIG	Justin Zelin	Maintained	Buy	$56
Nov 24, 2025	Barclays	Etzer Darout	PT Raise	Overweight	$22→$35
Nov 12, 2025	JP Morgan	Anupam Rama	PT Cut	Overweight	$40→$33
Nov 4, 2025	UBS	David Dai	PT Raise	Buy	$35→$38
Nov 4, 2025	Barclays	Peter Lawson	PT Raise	Overweight	$19→$22
Oct 27, 2025	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $38 price target.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33

UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $33.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and lowers the price target from $44 to $40.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $40 to $38.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $40 price target.

Benzinga Newsdesk

Syndax Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Syndax Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target

PRO
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33

PRO
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40

PRO
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

People Also Watch

People Also Watch

Syndax Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Syndax Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target

PROUBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33

PROJP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40

PROHC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38

PROHC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

PROHC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target

PRO
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33

PRO
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40

PRO
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target